AC 003
Alternative Names: AC-003Latest Information Update: 28 Mar 2025
At a glance
- Originator Accropeutics
- Class Anti-inflammatories; Antifibrotics; Antirheumatics; Small molecules
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Graft-versus-host disease; Idiopathic pulmonary fibrosis; Rheumatoid arthritis; Ulcerative colitis; Unspecified
Most Recent Events
- 13 Feb 2025 Phase-I clinical trials in Graft-versus-host disease in China (PO) (Accropeutics pipeline, February 2025)
- 13 Feb 2025 Phase-I clinical trials in Idiopathic pulmonary fibrosis (PO) (Accropeutics pipeline, February 2025)
- 13 Feb 2025 Phase-I clinical trials in Rheumatoid arthritis (PO) (Accropeutics pipeline, February 2025)